Download PDF
CC BY-NC-ND 4.0 · Journal of Clinical Interventional Radiology ISVIR 2021; 05(03): 136-141
DOI: 10.1055/s-0041-1728975
Original Article

Endovascular Stenting for Malignant Obstruction of Superior Vena Cava: A Single-Center Experience Using the Body Floss Technique

Dayananda Lingegowda
1   Department of Radiology, Tata Medical Center, Newtown, Kolkata, West Bengal, India
,
Bharat Gupta
1   Department of Radiology, Tata Medical Center, Newtown, Kolkata, West Bengal, India
,
Anisha Gehani
1   Department of Radiology, Tata Medical Center, Newtown, Kolkata, West Bengal, India
,
Priya Ghosh
1   Department of Radiology, Tata Medical Center, Newtown, Kolkata, West Bengal, India
,
Sumit Mukhopadhyay
1   Department of Radiology, Tata Medical Center, Newtown, Kolkata, West Bengal, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Purpose Endovascular stenting is the treatment of choice for malignant obstruction of the superior vena cava (SVC) when rapid symptomatic relief is desired. Body floss technique is not routinely used during SVC stenting but has few advantages over single-access technique. We report our experience with stenting for malignant obstruction of the SVC using the body floss technique.

Materials and Methods Between March 2015 and March 2020, 25 patients (20 men, 5 women; median age, 65 years) with malignant SVC obstruction underwent endovascular stenting of the SVC. We retrospectively evaluated these patients for clinical and technical success rates, complications, recurrence-free survival, and overall survival.

Results Stent placement was successful in 24/25 patients (technical success: 96%). Clinical success was achieved in 23/25 (92%) patients. A mortality rate of 4% (1/25) was noted due to SVC rupture. Partial stent migration was noted in two patients (8%) and was treated by placing an additional overlapping stent. Incidental early stent thrombosis was seen in two patients within 8 hours of stent placement, but these patients showed symptom relief with anticoagulation. Follow-up imaging confirmed stent patency in all patients. Late stent occlusion due to tumor progression was seen in one patient. The primary patency rate was 88% (22/25). Overall median survival of 133 days was observed (range: 1–847 days).

Conclusion Endovascular stenting of the SVC for malignant obstruction using the body floss technique is associated with high technical and clinical success, and low rate of complications.

Keywords

superior vena cava obstruction syndrome - SVC obstruction - body floss technique


Publication History

Article published online:
14 April 2021

© 2021. Indian Society of Vascular and Interventional Radiology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Lepper PM, Ott SR, Hoppe H. et al Superior vena cava syndrome in thoracic malignancies. Respir Care 2011; 56 (05) 653-666
    CrossrefPubMedGoogle Scholar
  • 2 Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. Am J Surg 1990; 160 (02) 207-211
    CrossrefPubMedGoogle Scholar
  • 3 Parish JM, Marschke RF Jr, Dines DE, Lee RE. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 1981; 56 (07) 407-413
    PubMedGoogle Scholar
  • 4 Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Intervent Radiol 2006; 29 (03) 319-322
    CrossrefPubMedGoogle Scholar
  • 5 Straka C, Ying J, Kong F-M, Willey CD, Kaminski J, Kim DWN. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. Springerplus 2016; 5: 229
    CrossrefPubMedGoogle Scholar
  • 6 Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome–a proposed classification system and algorithm for management. J Thorac Oncol 2008; 3 (08) 811-814
    CrossrefPubMedGoogle Scholar
  • 7 Kishi K, Sonomura T, Mitsuzane K. et al Self-expandable metallic stent therapy for superior vena cava syndrome: clinical observations. Radiology 1993; 189 (02) 531-535
    CrossrefPubMedGoogle Scholar
  • 8 Lanciego C, Pangua C, Chacón JI. et al Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome. Am J Roentgenol 2009; 193 (02) 549-558
    CrossrefPubMedGoogle Scholar
  • 9 Uberoi R. CIRSE Quality Assurance Guidelines for Superior Vena Cava Stenting in Malignant Disease. CardioVasc Interv Radiol 2006; 29: 319-322
    CrossrefPubMedGoogle Scholar
  • 10 Ganeshan A, Hon LQ, Warakaulle DR, Morgan R, Uberoi R. Superior vena caval stenting for SVC obstruction: current status. Eur J Radiol 2009; 71 (02) 343-349
    CrossrefPubMedGoogle Scholar
  • 11 Fagedet D, Thony F, Timsit J-F. et al Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. Cardiovasc Intervent Radiol 2013; 36 (01) 140-149
    CrossrefPubMedGoogle Scholar
  • 12 Tanigawa N, Sawada S, Mishima K. et al Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment. Acta Radiol 1998; 39 (06) 669-674
    CrossrefPubMedGoogle Scholar
  • 13 Rachapalli V, Boucher L-M. Superior vena cava syndrome: role of the interventionalist. Can Assoc Radiol J 2014; 65 (02) 168-176
    CrossrefPubMedGoogle Scholar
  • 14 Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 1984; 2 (08) 961-969
    CrossrefPubMedGoogle Scholar
  • 15 Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356 (18) 1862-1869
    CrossrefPubMedGoogle Scholar
  • 16 Dinkel H-P, Mettke B, Schmid F, Baumgartner I, Triller J, Do D-D. Endovascular treatment of malignant superior vena cava syndrome: is bilateral Wallstent placement superior to unilateral placement?. J Endovasc Ther 2003; 10 (04) 788-797
    CrossrefPubMedGoogle Scholar
  • 17 Chang S-N, Chi N-H, Lee W-J, Hsu K-L, Chiang F-T, Tseng C-D. Cardiac tamponade after stenting for superior vena cava obstruction. Zhonghua Minguo Xinzangxue Hui Zazhi 2009; 25: 161-164
    PubMedGoogle Scholar
  • 18 Taylor JD, Lehmann ED, Belli A-M. et al Strategies for the management of SVC stent migration into the right atrium. Cardiovasc Intervent Radiol 2007; 30 (05) 1003-1009
    CrossrefPubMedGoogle Scholar